Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 271
Rating:

Dr Elizabeth Pease - AstraZeneca, UK

Dr Elizabeth Pease speaks to ecancer at the WIN 2019 Symposium in Paris about the use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies.

She explains that by combining drugs the hope is that responses are deeper and more durable.

Dr Pease explains that developing these combinations is tricky and that it is important to look into the dosing, schedule and application to the right patient populations in order to maximise the benefit.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation